Overall, the findings from the ALKA-372-001, STARTRK-1, and STARTRK-2 studies underscore the clinical benefit of entrectinib in patients with NTRK fusion-positive tumours and ROS1-positive NSCLC, reaffirming its role as a promising targeted therapy in oncology [74,85,86,87]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.